Patients continue to inspire and drive us to the leading edge of precision medicine.* Along the way, these heroic acts of leadership and focus need to be translated into functional business models that can be widely adopted to transform our research and clinical care enterprise.
In this year’s conference on Wednesday, June 21 (agenda below), we address the question of how to implement and disseminate these business models head on. Fortunately there are already several enterprises, some of them led by patients themselves, which provide us early answers to these questions. These are featured in our first panel entitled Early Disruptors in Precision Medicine.
As we have noted in our prior conferences, some of the most interesting initiatives have come out of academic centers and others out of purely commercial initiatives. In our second panel entitled Academia and Industry—How Can We Play to Win?, we explore how these two wellsprings of innovation can best work together.
If we are going to succeed in the goals articulated for precision medicine, some means of measuring our success, particularly for patients and improving health, should be applied. This will allow us as a society to be more agile in finding new solutions. But without a “consumer reports” like function, progress will be difficult to measure. Our third panel, How Do We Guide the Consumer in the Precision Medicine Era?, discusses how we might think about such a consumer reports-like function and where it might sit relative to other benchmarking and regulatory processes.
Our opening keynote brings us back to the roots of this conference, which is the imperative to treat patients more successfully using the latest in clinical and molecular technology. Shirley Pepke will give us a summary of her harrowing and compelling journey to develop a successful survival plan for herself, in the face of deadly disease.
Our closing keynote is by Bob Kocher, who not only is one of the most successful healthcare venture entrepreneurs but also was one of the shapers of the Affordable Care Act, focusing on cost, quality, and delivery system reform and health IT policy during the Obama administration. From his vantage point, covering both the governmental and innovator’s perspectives, he will give us a look into the future of business models for managing and curing diseases both rare and common.